DeutschNewstral
Article
The Hindu on 2021-04-21 13:24
Updated data from Covaxin phase 3 trial shows 78% efficacy
Related news
- Bharat Biotech releases Covaxin Phase-3 trial data, claims 77.8% efficacyThe Hindu
Covaxin phase 3 data shows 77.8% efficacy: LancetThe Times of India- Covaxin safe, shows 77.8% efficacy against symptomatic COVID-19: Lancet studyThe Hindu
- CResults of India’s Covaxin vaccine by 15 August: fact checks , phase 1 completedcychron.com
- Covaxin data given to WHO for nodThe Hindu
- Coronavirus | Covaxin phase-1 trial results show promising resultsThe Hindu
- Covid-19: Why 50% Covaxin efficacy may not be as bad as it seemsThe Times of India
- Covaxin phase 2 trials show vaccine safe, induces immune responseThe Hindu
- Bharat Biotech says COVID-19 vaccine Covaxin shows 81% interim efficacyThe Hindu
- More data on Covaxin jabs for children soughtThe Hindu
- Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical holdThe Times of India
COVAXIN, ZyCoV-D move to phase 2 trials; SII to begin testing for Oxford COVID-19 vaccine next weekherald.co.zw- Coronavirus | I would not take the vaccine without efficacy data: Gagandeep KangThe Hindu
- Coronavirus | Covaxin yet to show potency against U.K. strainThe Hindu
- DCGI nod for Covaxin human trialsThe Hindu
- Docs slam ICMR's deadline for launching CovaxinThe Times of India
- How monkeys were tracked for Covaxin trial!The Times of India
- BHomegrown Indian Covid Vaccine Already in Use Shows 78% Efficacybloomberg.com
- Oxford vaccine shows 90% efficacy in Phase-3 trialThe Hindu
- Month after month, Covaxin missing production targetThe Times of India